On 12th December, the Australian NPC Disease Foundation hosted a virtual meet and greet with Cyclo Therapeutics, a biotechnology company developing a potential treatment for Niemann-Pick disease type C (NPC).
The meet and greet featured a presentation by Dr. Caroline Hastings, a paediatric neurologist and an investigator in the clinical trials of Trappsol Cyclo, the drug candidate developed by Cyclo Therapeutics. Dr. Hastings explained the mechanism of action, the dosing regimen, and the outcomes of Trappsol Cyclo, which is a cyclodextrin-based therapy that aims to reduce the accumulation of cholesterol and other lipids in NPC cells. She also answered questions from the audience about the safety, efficacy, and availability of the treatment.
The meet and greet was a valuable opportunity for the NPC community to connect with Cyclo Therapeutics and learn more about their work and vision. The Australian NPC Disease Foundation thanked Cyclo Therapeutics for their collaboration and dedication to finding a cure for NPC, and expressed their gratitude to all the participants for joining the event.
If you missed the event or want to watch it again, you can view it here: